ArticleCureus2026
Diffuse Large B-Cell Lymphoma Presenting With Isolated Splenomegaly in a 42-Year-Old Female: A Rare Incidence of Primary Splenic Involvement.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary splenic involvement by diffuse large B-cell lymphoma (DLBCL) is uncommon and may present with nonspecific clinical features, making diagnosis challenging. We report the case of a 42-year-old female who presented with gradually increasing abdominal distension and weight loss over three months, without fever, night sweats, or lymphadenopathy. Examination revealed massive splenomegaly, while routine laboratory tests were unremarkable. Ultrasound and CT imaging demonstrated isolated splenomegaly, and PET-CT showed increased metabolic activity confined to the spleen. Bone marrow biopsy did not reveal any diagnostic abnormalities. The patient underwent diagnostic splenectomy, and histopathology confirmed DLBCL of the non-germinal center B-cell subtype. Immunohistochemistry was positive for CD45, CD20, BCL2, and MUM1, with a Ki-67 index of 60%. She received six cycles of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy, which she tolerated well. Post-treatment PET-CT revealed a complete metabolic response, and subsequent follow-up has shown no evidence of disease recurrence. This report illustrates that isolated splenomegaly can be the first and only manifestation of DLBCL and emphasizes the role of splenectomy as both a diagnostic and therapeutic option in carefully selected patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.